{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:51Z","timestamp":1792022451377,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1124\/dmd.105.007369","type":"journal-article","created":{"date-parts":[[2005,12,29]],"date-time":"2005-12-29T01:13:12Z","timestamp":1135818792000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":229,"title":["SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) \u201cPROBES\u201d FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES"],"prefix":"10.1016","volume":"34","author":[{"given":"Verawan","family":"Uchaipichat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter I.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Elliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.105.007369_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00003088-197803050-00003","article-title":"Clinical pharmacokinetics of phenylbutazone.","volume":"3","author":"Aarbakke","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.105.007369_bib2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance and its prediction from physicochemical properties.","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2125.2002.01669.x","article-title":"In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.","volume":"54","author":"Boase","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.105.007369_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.2005.02446.x","article-title":"S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.","volume":"60","author":"Bowalgaha","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.105.007369_bib5","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/004982598238877","article-title":"In vitro assessment of human cytochrome P450.","volume":"28","author":"Clarke","year":"1998","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.105.007369_bib6","first-page":"73","article-title":"The glucuronidation of opioids, other xenobiotics and androgens by human UGT2B7Y(268) and UGT2B7H(268).","volume":"26","author":"Coffman","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib7","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1124\/dmd.31.9.1125","article-title":"Evaluation of 3\u2032-azido-3\u2032-deoxythymidine, morphine and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.","volume":"31","author":"Court","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00614010","article-title":"Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man.","volume":"9","author":"Dieterle","year":"1975","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.105.007369_bib9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1124\/dmd.105.004333","article-title":"Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay.","volume":"33","author":"Di Marco","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/00365519950185832","article-title":"Aldosterone metabolism in cultures of rat renal cortical and medullary cells.","volume":"59","author":"Egfjord","year":"1999","journal-title":"Scand J Clin Lab Investig"},{"key":"10.1124\/dmd.105.007369_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0960-0760(99)00088-6","article-title":"Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7.","volume":"70","author":"Gall","year":"1999","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.105.007369_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/dmd.32.2.267","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0090-9556(25)07355-6","article-title":"Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein.","volume":"24","author":"Green","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15358-5","article-title":"In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.","volume":"28","author":"Houston","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/abbi.1997.9949","article-title":"The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11.","volume":"341","author":"Jin","year":"1997","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.105.007369_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clpt.2003.08.011","article-title":"Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.","volume":"74","author":"Kharasch","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.007369_bib17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1440-1681.1998.t01-19-.x","article-title":"Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors.","volume":"25","author":"Kirkwood","year":"1998","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1124\/dmd.105.007369_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent.","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.105.007369_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00008571-199708000-00001","article-title":"The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence.","volume":"7","author":"Mackenzie","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.105.007369_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2125.2000.00193.x","article-title":"Nonspecific binding of drugs to human liver microsomes.","volume":"49","author":"McLure","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.105.007369_bib21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0006-2952(88)90140-2","article-title":"Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes.","volume":"37","author":"Miners","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.105.007369_bib22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0163-7258(91)90065-T","article-title":"Drug glucuronidation in humans.","volume":"51","author":"Miners","year":"1991","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.105.007369_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.44.101802.121546","article-title":"Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches.","volume":"44","author":"Miners","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.105.007369_bib24","first-page":"307","article-title":"In vitro approaches for the prediction of human drug metabolism.","volume":"29","author":"Miners","year":"1994","journal-title":"Annu Rep Med Chem"},{"key":"10.1124\/dmd.105.007369_bib25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-003-0637-8","article-title":"Metabolism and elimination of quinine in healthy volunteers.","volume":"59","author":"Mirghani","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.105.007369_bib26","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes.","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib27","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1081\/DMR-100101944","article-title":"Structural and functional studies of UDP-glucuronosyltransferases.","volume":"31","author":"Radominska-Pandya","year":"1999","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.105.007369_bib28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0090-9556(25)08724-0","article-title":"3\u2032-Azido-3\u2032-deoxythymidine drug interactions. Screening for inhibitors in human liver microsomes.","volume":"20","author":"Rajaonarison","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0006-2952(91)90319-Z","article-title":"Glucuronidation of 3\u2032-azido-3\u2032-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics.","volume":"42","author":"Resetar","year":"1991","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.105.007369_bib30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00008571-200211000-00008","article-title":"Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.","volume":"12","author":"Sorich","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.105.007369_bib31","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1124\/dmd.31.9.1086","article-title":"Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7 [erratum in Drug Metab Dispos (2003) 31: 1541].","volume":"31","author":"Stone","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferases: metabolism, expression and disease.","volume":"40","author":"Tukey","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.105.007369_bib33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents and inhibition by diclofenac and probenecid.","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.007369_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation.","author":"Uchaipichat","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.105.007369_bib35","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/00912700122012724","article-title":"Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.","volume":"41","author":"Venkatakrishnan","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.105.007369_bib36","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(87)92172-6","article-title":"Antidepressants increase bioavailability of morphine in cancer patients.","volume":"1","author":"Ventafridda","year":"1987","journal-title":"Lancet"},{"key":"10.1124\/dmd.105.007369_bib37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/0002-9149(78)90851-2","article-title":"Pharmacokinetics of antiarrhythmic drugs.","volume":"41","author":"Woosley","year":"1978","journal-title":"Am J Cardiol"},{"key":"10.1124\/dmd.105.007369_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1600-0773.1990.tb00737.x","article-title":"Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors.","volume":"66","author":"Yue","year":"1990","journal-title":"Pharmacol Toxicol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624034251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624034251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.105.007369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:01:00Z","timestamp":1739901660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624034251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0090955624034251"],"URL":"https:\/\/doi.org\/10.1124\/dmd.105.007369","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) \u201cPROBES\u201d FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.105.007369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}